Endometrial Cancer Research and Education Act of 2020

Bill: 116-hr-5794
Sponsor: full_name: Rep. Scott, David [D-GA-13]
Introduced: 2020-02-06
Policy area: Health
Subjects: Cancer

Disability and health-based discrimination

Health promotion and preventive care

Medical research

Racial and ethnic relations

Research and development

Women's health
Latest action: action_date: 2020-02-06
text: Referred to the House Committee on Energy and Commerce.

Summaries:
action_date: 2020-02-06
action_desc: Introduced in House
text: <p><b>Endometrial Cancer Research and Education Act of 2020</b></p> <p>This bill requires the National Institutes of Health and the Centers for Disease Control and Prevention to expand research and develop certain educational materials on endometrial cancer, respectively. Among other issues, the materials must address certain endometrial cancer disparities and risk factors that affect minority women. </p>

tv_txt: I 116th CONGRESS 2d Session H. R. 5794 IN THE HOUSE OF REPRESENTATIVES February 6, 2020 Mr. David Scott of Georgia (for himself, Ms. Norton , Mr. Cohen , Mrs. Beatty , Ms. Kelly of Illinois , Mr. Bishop of Georgia , Mr. Butterfield , Mr. Carson of Indiana , Ms. Clarke of New York , Mr. Thompson of Mississippi , Ms. Pressley , Mr. Lawson of Florida , Mr. Hastings , Ms. Blunt Rochester , Ms. Johnson of Texas , Mr. Green of Texas , Ms. Fudge , Mr. Payne , Ms. Bass , Ms. Lee of California , Mr. Rush , Mr. Brown of Maryland , Mr. Danny K. Davis of Illinois , Mr. Richmond , Mr. Jeffries , Mr. Meeks , Ms. Jackson Lee , Mr. Johnson of Georgia , Mrs. Watson Coleman , Ms. Plaskett , and Mr. Clyburn ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Public Health Service Act to expand research and education with respect to endometrial cancer, and for other purposes.

1. Short title This Act may be cited as the Endometrial Cancer Research and Education Act of 2020 . 2. Findings Congress finds the following: (1) Endometrial cancer is cancer of the lining of the uterus (or endometrium) and is the most common form of uterine cancer. (2) Endometrial cancer is the fourth most common cancer diagnosed in women, after breast, lung, and colon cancer. (3) Endometrial cancer mainly affects postmenopausal women, with most women diagnosed between age 55 and 64. (4) Women with polycystic ovary syndrome (PCOS) and uterine leiomyoma have an increased risk of developing endometrial cancer. (5) Unlike most other types of cancer, the incidence of endometrial cancer, particularly aggressive subtypes of such cancer, has been increasing in the United States among all women, particularly among African-American and Asian women, with a 2.5 annual percent change for both groups. (6) In comparison to non-Hispanic White women, African-American women have significantly higher incidence rates of aggressive endometrial cancers. (7) Such incidence rates for Hispanic and Asian women are equal to or lower than such incidence rates for non-Hispanic White women. (8) Although non-Hispanic White women are more likely to be diagnosed with endometrial cancer in comparison to African-American women, the rate of mortality is higher for African-American women. (9) Currently, the cause of such disparity is unknown. Researchers have studied the disparity in relation to the time between diagnosis and treatment of endometrial cancer, including socioeconomic factors. 3. Expanding research and education with respect to endometrial cancer (a) National Institutes of Health Part B of title IV of the Public Health Service Act ( 42 U.S.C. 284 et seq.) is amended by adding at the end the following new section: 409K. Endometrial cancer (a) In general The Director of NIH shall— (1) expand, intensify, and coordinate programs to conduct and support research with respect to endometrial cancer; and (2) communicate to medical professionals and researchers, including through the endometrial cancer public education program established under section 399V–7, the disparity in the diagnosis of endometrial cancer between African-American women and non-Hispanic White women and any new research relating to endometrial cancer. (b) Coordination with other institutes The Director of NIH shall coordinate activities carried out by the Director pursuant to subsection (a) with similar activities carried out by— (1) the Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development; (2) the Director of the National Institute on Minority Health and Health Disparities; and (3) the Director of the Office of Research on Women’s Health. (c) Authorization of appropriations For purposes of carrying out this section, there is authorized to be appropriated $500,000 for each of fiscal years 2021 through 2023. . (b) Centers for Disease Control and Prevention Part P of title III of the Public Health Service Act ( 42 U.S.C. 280g et seq.) is amended by adding at the end the following new section: 399V–7. Endometrial Cancer Public Education Program (a) In general The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall develop and disseminate to the public informational materials on endometrial cancer, including the incidence rate of such cancer, the risk factors for developing such cancer, the increased risk for ethnic minority women to develop such cancer, and the range of available treatments for such cancer. Any informational material developed pursuant to the previous sentence may be transmitted to a nonprofit organization; institution of higher education; Federal, State, or local agency; or media entity for purposes of disseminating such material to the public. (b) Consultation In developing and disseminating informational materials under subsection (a), the Director of the Centers for Disease Control and Prevention shall consult with the Administrator of the Health Resources and Services Administration. (c) Authorization of appropriations For purposes of carrying out this section, there is authorized to be appropriated such sums as may be necessary for each of fiscal years 2021 through 2023. .